Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HTR6 | P50406 | 9/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4526571 | 0.84 | HTR2C (0.37) | ALDH1A1HTR6HTR2CHTR2B | |
| SCHEMBL9940358 | 0.84 | GAA (0.37) | HTR6 | |
| SCHEMBL9131888 | 0.78 | HTR6 (0.40) | HTR6HTR2CHTR2B | |
| SCHEMBL651876 | 0.76 | KMT2A (0.38) | ALDH1A1HSD17B10MAPT | |
| SCHEMBL334411 | 0.76 | HTR6 (0.45) | HTR6 | |
| SCHEMBL336837 | 0.70 | HTR2A (0.45) | MAPTHTR6HTR2CHTR2A | |
| SCHEMBL571789 | 0.69 | SLC18A3 (0.41) | ALDH1A1HSD17B10TDP1MAPT | |
| SCHEMBL15533822 | 0.69 | MAPT (0.40) | ALDH1A1MAPTHTR6HTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL3547060 | 0.69 | HTR2A (0.44) | MAPTHTR6HTR2CHTR2A | |
| SCHEMBL335650 | 0.69 | APLNR (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050032795-A1 | 2-Amino-benzoxazinones for the treatment of herpes simplex virus | G.D. SEARLE & CO. (US) | 2005-02-10 | — | — | US | claimed |
| US-20030236403-A1 | Certain substituted 1-aryl-3-piperazine-1'-yl propanones | MOLECULAR GERIATRICS CORPORATION (US) | 2003-12-25 | — | — | US | claimed |
| US-20010025105-A1 | Certain substituted 1-aryl-3-piperazine-1'-yl propanones | MOLECULAR GERIATARICS CORPORATION | 2001-09-27 | — | — | US | claimed |
| EP-0792269-A2 | CERTAIN SUBSTITUTED 1-ARYL-3-PIPERAZIN-1'-YL PROPANONES | MOLECULAR GERIATRICS CORPORATION (US) | 1997-09-03 | — | — | EP | claimed |
| EP-0438230-B1 | Indole-substituted five-membered heteroaromatic compounds | MERCK SHARP & DOHME (GB) | 1997-04-23 | — | — | EP | claimed |
| WO-1996015792-A9 | METHODS FOR TREATING OR PREVENTING ALZHEIMER'S DISEASE USING SUBSTITUTED 1-ARYL-3-PIPERAZIN-1'-YL PROPANONES | — | 1996-09-12 | — | — | WO | claimed |
| WO-1996016052-A2 | CERTAIN SUBSTITUTED 1-ARYL-3-PIPERAZIN-1'-YL PROPANONES | MOLECULAR GERIATRICS CORPORATION (US) | 1996-05-30 | — | — | WO | claimed |
| WO-1996015792-A1 | METHODS FOR TREATING OR PREVENTING ALZHEIMER'S DISEASE USING SUBSTITUTED 1-ARYL-3-PIPERAZIN-1'-YL PROPANONES | MOLECULAR GERIATRICS CORPORATION (US) | 1996-05-30 | — | — | WO | claimed |
| EP-3226858-A1 | IMIDAZOLE-BASED ANTIMICROBIAL AGENTS | Procomcure Biotech GmbH (AT) | 2017-10-11 | — | — | EP | disclosed |
| WO-2016087615-A1 | NOVEL IMIDAZOLE-BASED HETEROCYCLIC COMPOUNDS | PROCOMCURE BIOTECH GMBH (AT) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016087616-A1 | IMIDAZOLE-BASED ANTIMICROBIAL AGENTS | PROCOMCURE BIOTECH GMBH (AT) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016087618-A1 | IMIDAZOLE-BASED ANTIMICROBIAL AGENTS | PROCOMCURE BIOTECH GMBH (AT) | 2016-06-09 | — | — | WO | disclosed |
| EP-2300432-B1 | PIPERAZINE DERIVATIVES USED AS CAV2.2 CALCIUM CHANNEL MODULATORS | CONVERGENCE PHARMACEUTICALS (GB) | 2012-10-03 | — | — | EP | disclosed |
| US-7173132-B2 | Certain substituted 1-aryl-3-piperazine-1′-yl propanones | MOLECULAR GERIATRICS CORPORATION (US) | 2007-02-06 | — | — | US | disclosed |
| WO-1996016052-A2 | CERTAIN SUBSTITUTED 1-ARYL-3-PIPERAZIN-1'-YL PROPANONES | MOLECULAR GERIATRICS CORPORATION (US) | 1996-05-30 | — | — | WO | disclosed |
| WO-1996015792-A1 | METHODS FOR TREATING OR PREVENTING ALZHEIMER'S DISEASE USING SUBSTITUTED 1-ARYL-3-PIPERAZIN-1'-YL PROPANONES | MOLECULAR GERIATRICS CORPORATION (US) | 1996-05-30 | — | — | WO | disclosed |
| US-5317103-A | Migraine treatment | MERCK SHARP & DOHME LIMITED (GB) | 1994-05-31 | — | — | US | disclosed |
| US-5208248-A | Hydroxytryptamine Receptor Agonists | MERCK SHARPE & DOHME, LTD. (GB) | 1993-05-04 | — | — | US | disclosed |
| EP-0494774-A1 | Indazole-substituted fivemembered heteroaromatic compounds | MERCK SHARP & DOHME LTD. (GB) | 1992-07-15 | — | — | EP | disclosed |
| EP-0438230-A2 | Indole-substituted five-membered heteroaromatic compounds | MERCK SHARP & DOHME LTD. (GB) | 1991-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236403-A1 | Certain substituted 1-aryl-3-piperazine-1'-yl propanones | PSEN1, PSEN2, PRNP | ALDH1A1 3122/4885HSD17B10 3029/4885TDP1 2681/4885 |
| US-20050032795-A1 | 2-Amino-benzoxazinones for the treatment of herpes simplex virus | GABBR1, GABBR2, EBNA1BP2 | ALDH1A1 1799/4885HSD17B10 468/4885TDP1 1173/4885 |
| US-20010025105-A1 | Certain substituted 1-aryl-3-piperazine-1'-yl propanones | PSEN1, PSEN2, PRNP | ALDH1A1 3122/4885HSD17B10 3029/4885TDP1 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.